Nanwei Shares released its 2026 half-year report on August 30. First-half operating revenue was 271 million yuan, down 11.5% year on year. Net profit attributable to the parent swung from a loss of 12.97 million yuan in the same period last year to a loss of 17.79 million yuan, while net profit attributable to the parent excluding non-recurring items widened from a loss of 15.4 million yuan to a loss of 18.61 million yuan. Second-quarter revenue was 116 million yuan, down 14.4% year on year, and the net loss attributable to the parent was 12.7 million yuan, wider than the 5.05 million yuan loss a year earlier. As of the end of the second quarter, total assets stood at 875 million yuan, down 5.7% from the end of the previous year, and net assets attributable to the parent were 159 million yuan, down 10.04%. The company said the revenue decline was mainly due to market factors that reduced revenue across product lines, the profit decline was caused by intense market competition and lower revenue, and the decrease in operating cash flow was due to a reduction in other cash received from operating activities. During the reporting period, research and development spending was 10.96 million yuan, aimed at consolidating its technical advantages in transdermal products.
Jiangsu Nanfang MedicalH1 revenue fell 11.5% and net loss widened to 17.79 million yuan, reflecting weak financial performance.
